Literature DB >> 8796870

The NADPH oxidase and chronic granulomatous disease.

A W Segal1.   

Abstract

Chronic granulomatous disease (CGD) is characterized by severe, protracted and often fatal infection, which results from a failure of the NADPH oxidase enzyme system in the patient's phagocytes to produce superoxide. The NADPH oxidase enzyme system is composed of a number of interacting components, the absence of any one of which causes failure of the system as a whole. Investigation of individuals with CGD has led to the identification of the different protein components and the genes coding for them. CGD is particularly well suited to treatment by gene therapy and is likely to be one of the earliest monogenic conditions to be successfully treated in this way.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8796870     DOI: 10.1016/1357-4310(96)88723-5

Source DB:  PubMed          Journal:  Mol Med Today        ISSN: 1357-4310


  33 in total

1.  The mechanism of activation of NADPH oxidase in the cell-free system: the activation process is primarily catalytic and not through the formation of a stoichiometric complex.

Authors:  A R Cross; R W Erickson; J T Curnutte
Journal:  Biochem J       Date:  1999-07-15       Impact factor: 3.857

Review 2.  Ophthalmic manifestations of immunodeficiency states.

Authors:  R Rescigno; M Dinowitz
Journal:  Clin Rev Allergy Immunol       Date:  2001-04       Impact factor: 8.667

3.  Role of the phagosomal redox-sensitive TRP channel TRPM2 in regulating bactericidal activity of macrophages.

Authors:  Anke Di; Tomohiro Kiya; Haixia Gong; Xiaopei Gao; Asrar B Malik
Journal:  J Cell Sci       Date:  2017-01-12       Impact factor: 5.285

Review 4.  Gene therapy of chronic granulomatous disease: the engraftment dilemma.

Authors:  Manuel Grez; Janine Reichenbach; Joachim Schwäble; Reinhard Seger; Mary C Dinauer; Adrian J Thrasher
Journal:  Mol Ther       Date:  2010-11-02       Impact factor: 11.454

5.  Nox5 forms a functional oligomer mediated by self-association of its dehydrogenase domain.

Authors:  Tsukasa Kawahara; Heather M Jackson; Susan M E Smith; Paul D Simpson; J David Lambeth
Journal:  Biochemistry       Date:  2011-03-04       Impact factor: 3.162

Review 6.  NADPH oxidases: an overview from structure to innate immunity-associated pathologies.

Authors:  Arvind Panday; Malaya K Sahoo; Diana Osorio; Sanjay Batra
Journal:  Cell Mol Immunol       Date:  2014-09-29       Impact factor: 11.530

7.  p47phox molecular activation for assembly of the neutrophil NADPH oxidase complex.

Authors:  Julien Marcoux; Petr Man; Isabelle Petit-Haertlein; Corinne Vivès; Eric Forest; Franck Fieschi
Journal:  J Biol Chem       Date:  2010-06-30       Impact factor: 5.157

Review 8.  Concise review: lessons learned from clinical trials of gene therapy in monogenic immunodeficiency diseases.

Authors:  David A Williams; Adrian J Thrasher
Journal:  Stem Cells Transl Med       Date:  2014-03-28       Impact factor: 6.940

9.  Nonresolving inflammation in gp91phox-/- mice, a model of human chronic granulomatous disease, has lower adenosine and cyclic adenosine 5'-monophosphate.

Authors:  Ravindra Rajakariar; Justine Newson; Edwin K Jackson; Precilla Sawmynaden; Andrew Smith; Farooq Rahman; Muhammad M Yaqoob; Derek W Gilroy
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

10.  NADPH oxidase limits lipopolysaccharide-induced lung inflammation and injury in mice through reduction-oxidation regulation of NF-κB activity.

Authors:  Wei Han; Hui Li; Jiyang Cai; Linda A Gleaves; Vasiliy V Polosukhin; Brahm H Segal; Fiona E Yull; Timothy S Blackwell
Journal:  J Immunol       Date:  2013-03-25       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.